Enasidenib is a medication that belongs to a class of drugs known as IDH2 inhibitors. It is used in the treatment of a specific type of blood cancer called acute myeloid leukemia (AML) with an IDH2 mutation. This mutation causes the production of an abnormal protein that can lead to the uncontrolled growth of cancer cells.

Enasidenib works by targeting and inhibiting the mutated IDH2 enzyme, which helps to restore normal cell differentiation and slow down the growth of cancer cells. This can help to improve symptoms and increase the chances of remission in patients with AML.

It is important to note that Enasidenib is a prescription medication and should only be taken under the supervision of a healthcare provider experienced in the treatment of AML. Your doctor will determine the appropriate dosage and duration of treatment based on your individual medical history and response to the medication.

Like all medications, Enasidenib can cause side effects. Common side effects may include nausea, vomiting, diarrhea, fatigue, and decreased appetite. It is important to report any side effects to your healthcare provider so that they can be properly managed.

Overall, Enasidenib is a valuable treatment option for patients with AML who have an IDH2 mutation. It has shown promising results in clinical trials and has the potential to improve outcomes for individuals with this type of blood cancer. If you have been diagnosed with AML and have an IDH2 mutation, talk to your doctor about whether Enasidenib may be a suitable treatment option for you.